



# Left Atrial Appendage Closure: A Comprehensive Overview of Procedure, Indications, and Outcomes

Kai Cheng\*

Department of Cardiology, Wenzhou Medical University, China

## INTRODUCTION

The Left Atrial Appendage (LAA) closure is a significant medical procedure that has gained prominence in the management of Atrial Fibrillation (AF) and stroke prevention. As a non-pharmacological alternative to anticoagulant therapy, LAA closure has emerged as a valuable option for patients with specific risk factors and contraindications to long-term blood-thinning medications. To understand the rationale behind LAA closure, it is crucial to delve into the anatomy and physiology of the left atrial appendage. The left atrial appendage is a pouch-like extension of the left atrium, and it plays a role in cardiac function. However, in individuals with atrial fibrillation, blood stasis in the LAA increases the risk of thrombus formation, leading to embolic events, particularly strokes. LAA closure is typically considered for patients with atrial fibrillation who are at an increased risk of stroke but have contraindications to long-term anticoagulant therapy. The decision to undergo LAA closure is often based on individual patient characteristics, such as age, comorbidities, bleeding risk, and lifestyle factors. Indications may include: Patients with non-valvular atrial fibrillation are often candidates for LAA closure, especially when anticoagulation is not feasible or poses a high risk. Individuals who cannot tolerate anticoagulant medications due to bleeding risks, recurrent falls, or other contraindications may opt for LAA closure [1,2]. Patients who have experienced bleeding complications with anticoagulant therapy may choose LAA closure as an alternative to reduce the risk of stroke.

## DESCRIPTION

Several methods and devices are employed for LAA closure, each with its unique advantages and considerations. Surgical Ligation: Historically, surgical closure of the LAA was performed during open-heart surgery, particularly when patients were undergoing other cardiac procedures like valve replacements or coronary artery bypass grafting. Percutaneous Closure: The percutaneous or catheter-based approach has

gained popularity as a less invasive alternative. This involves deploying devices within the LAA to occlude it and prevent blood stagnation. Common devices include the Watchman, Amplatzer Cardiac Plug, and Lariat. The Watchman device is one of the most widely used percutaneous LAA closure devices. It is a self-expanding nitinol device shaped like a parachute that is delivered through a transseptal puncture. The device is deployed in the LAA to occlude it, reducing the risk of thrombus formation. The Watchman procedure involves several steps, including transseptal puncture, LAA sizing, and device deployment. The implantation is typically performed under fluoroscopic and echocardiographic guidance [3,4]. Multiple clinical trials, including the PROTECT AF and PREVAIL trials, have demonstrated the efficacy and safety of the Watchman device. These trials compared LAA closure with warfarin and showed non-inferiority in terms of stroke prevention.

## CONCLUSION

Left atrial appendage closure has emerged as a valuable therapeutic option for stroke prevention in patients with atrial fibrillation. The procedure offers an alternative to long-term anticoagulant therapy, especially for individuals with contraindications or intolerance to blood-thinning medications. With the evolution of devices and procedural techniques, LAA closure continues to demonstrate efficacy in reducing the risk of stroke while minimizing bleeding complications. As research and technological advancements progress, the landscape of LAA closure will likely expand, providing clinicians with additional tools to tailor treatment to individual patient needs.

## ACKNOWLEDGEMENT

None.

## CONFLICT OF INTEREST

The author's declared that they have no conflict of interest.

<b>Received:</b>	31-January-2024	<b>Manuscript No:</b>	IPIC-23-19066
<b>Editor assigned:</b>	02-February-2024	<b>PreQC No:</b>	IPIC-23-19066 (PQ)
<b>Reviewed:</b>	16-February-2024	<b>QC No:</b>	IPIC-23-19066
<b>Revised:</b>	21-February-2024	<b>Manuscript No:</b>	IPIC-23-19066 (R)
<b>Published:</b>	28-February-2024	<b>DOI:</b>	10.21767/2471-8157.10.02.12

**Corresponding author** Kai Cheng, Department of Cardiology, Wenzhou Medical University, China, E-mail: chengk@sina.com

**Citation** Cheng K (2024) Left Atrial Appendage Closure: A Comprehensive Overview of Procedure, Indications, and Outcomes. *Interv Cardiol J.* 10:12.

**Copyright** © 2024 Cheng K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## REFERENCES

1. Nagasaka T, Nakamura M (2023) Left atrial appendage closure: A narrative review. *Cardiol Ther* 12(4):615-635.
2. Sanchez CE, Yakubov SJ, Amin A, Arshi A (2020) Left atrial appendage closure: Technical considerations of endocardial closure. *Card Electrophysiol Clin* 12(1):47-54.
3. Saraf K, Morris GM (2022) Left atrial appendage closure: What the evidence does and does not reveal-a view from the outside. *Interv Cardiol Clin* 11(2):171-183.
4. Skurk C, Seppelt C, Meteeva D, Rheinthal M, Landmesser U (2021) Left atrial appendage closure: Current data and future developments. *Herz* 46(5):452-466.